[{"indications": "Indications\u00a0type 2 diabetes mellitus", "name": "GLIMEPIRIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.1 Sulfonylureas", "GLIMEPIRIDE"], "cautions": "Cautions\u00a0\n(From 6.1.2.1 Sulfonylureas: British National Formulary)\nCautions\u00a0Sulfonylureas can encourage weight gain and should be prescribed only if poor control and symptoms persist despite adequate attempts at dieting; metformin (section 6.1.2.2) is considered the drug of choice in obese patients. Caution is needed in the elderly and in patients with G6PD deficiency (section 9.1.5).; manufacturer recommends\r\nregular hepatic and haematological monitoring but limited evidence\r\nof clinical value; interactions: Appendix\r\n1 (antidiabetics)", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129593.htm", "doses": ["Initially 1\u00a0mg daily, adjusted according to response in\r\n1-mg steps at 1\u20132 week intervals; usual max. 4\u00a0mg daily (exceptionally,\r\nup to 6\u00a0mg daily may be used); taken shortly before or with first\r\nmain meal"], "pregnancy": "Pregnancy\u00a0\n(From 6.1.2.1 Sulfonylureas: British National Formulary)\nPregnancy\u00a0The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia; however, glibenclamide can be used during the second and third trimesters of pregnancy in women with gestational diabetes, see section 6.1.2."}]